Methods and compositions for CNS delivery of iduronate-2-sulfatase

Patent metadata

Field	Value
Publication number	US-11260112-B2
Application number	US-201916515568-A
Country	US
Kind code	B2
Filing date	Jul 18, 2019
Priority date	Jun 25, 2010
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

First claim

What is claimed is:

1. A method of treating Hunter Syndrome comprising a step of administering intracerebroventricularly (ICV) to a human subject in need of treatment a formulation comprising an iduronate-2-sulfatase (I2S) protein at a concentration of at least 5 mg/ml at a dose amount of at least 10 mg.

2. The method of claim 1 , wherein the formulation contains a phosphate concentration no greater than 20 mM.

3. The method of claim 2 , wherein the formulation comprises phosphate at a concentration of no greater than 5 mM.

4. The method of claim 1 , wherein the I2S protein is present at a concentration of at least about 10 mg/ml.

5. The method of claim 1 , wherein the I2S protein is present at a concentration of approximately 30 mg/ml.

6. The method of claim 1 , wherein the I2S protein comprises an amino acid sequence of SEQ ID NO:1.

7. The method of claim 1 , wherein the formulation further comprises salt.

8. The method of claim 7 , wherein the salt is NaCl.

9. The method of claim 1 , wherein the formulation further comprises polysorbate.

10. The method of claim 9 , wherein the polysorbate is polysorbate 20 present at a concentration of approximately 0.005-0.02%.

11. The method of claim 1 , wherein the formulation has a pH of approximately 5.5-6.5.

12. The method of claim 1 , wherein the formulation is a liquid formulation.

13. The method of claim 1 , wherein the formulation is formulated as lyophilized dry powder.

14. The method of claim 1 , wherein the formulation further comprises NaCl at a concentration of approximately 154 mM, polysorbate 20 at a concentration of approximately 0.005%, and a pH of approximately 6.

15. The method of claim 1 , wherein the I2S protein is a synthetic, recombinant, gene-activated or natural enzyme.

16. The method of claim 1 , wherein the formulation is administered in a volume of about 1-15 ml.

17. A method of treating Hunter Syndrome, comprising a step of administering intracerebroventricularly (ICV) to a human subject in need of treatment a formulation comprising an iduronate-2-sulfatase (I2S) protein at a concentration at or greater than 5 mg/ml, salt at a concentration of approximately 154 mM, a polysorbate surfactant at a concentration of approximately 0-0.02%, and a pH of approximately 5.5-6.5; wherein the formulation is administered at a volume of about 1-5 ml, and wherein the formulation is administered at a dose amount of at least 10 mg.

Assignees

• Shire Human Genetic Therapies

Inventors

• Zhu Gaozhong
• Lowe Kris
• Shahrokh Zahra
• Christian James
• Fahrner Richard
• Pan Jing
• Wright Teresa Leah
• Calias Pericles

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C12Y310/01001

  N-Sulfoglucosamine sulfohydrolase (3.10.1.1) · CPC title

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title